Trium Capital’s Amedisys AMED Stock Holding History

Trium Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,693	Closed	-$339K	–	65
2024 Q2	$339K	Buy	+3,693	New	+$343K	0.04%	81

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Trium Capital's AMED Position: Q3 2024 in Review

Trium Capital sold out of Amedisys (AMED) in Q3 2024, closing a stake of 3,693 shares — an estimated $339K sold.

Trium Capital first reported a position in AMED in Q2 2024 and held it in 1 quarter. The position peaked at $339K in Q2 2024. 285 funds tracked by Wall St. Rank hold AMED as of Q3 2024.

Trium Capital reported no remaining Amedisys position as of Q3 2024 after selling out during the quarter.
Trium Capital sold 3,693 Amedisys shares in Q3 2024, an estimated $339K.
Trium Capital first reported a position in Amedisys in Q2 2024 and held it in 1 quarter.
Trium Capital's Amedisys position peaked at $339K in Q2 2024.
285 funds tracked by Wall St. Rank held Amedisys as of Q3 2024.

Based on Trium Capital's 13F filing for Q3 2024, filed 7 Oct 2024.